primari
biliari
cirrhosi
pbc
immunemedi
chronic
progress
inflammatori
liver
diseas
lead
destruct
small
interlobular
bile
duct
progress
cholestasi
eventu
fibrosi
cirrhosi
liver
without
medic
treatment
commonli
necessit
liver
transplant
addison
gull
first
describ
diseas
pbclike
pictur
term
primari
biliari
cirrhosi
coin
cohort
patient
characterist
featur
pbc
publish
pbc
predominantli
affect
middleag
women
character
biochem
marker
cholestasi
serum
antimitochondri
autoantibodi
ama
lymphocyt
infiltr
portal
tract
liver
histolog
hallmark
diseas
damag
biliari
epitheli
cell
bec
loss
small
intrahepat
bile
duct
accompani
signific
portal
tract
infiltr
cell
b
cell
macrophag
eosinophil
natur
killer
cell
one
first
condit
specif
autoantibodi
recogn
pbc
regard
model
autoimmun
diseas
environment
factor
inherit
genet
predisposit
appear
contribut
pathogenesi
although
tremend
progress
unravel
potenti
pathophysiolog
factor
pbc
past
year
actual
impact
identifi
genet
environment
associ
still
controversi
aim
articl
review
current
knowledg
major
patholog
featur
pbc
tri
combin
find
overal
pictur
pathogenesi
pbc
frequent
symptom
pbc
fatigu
pruritu
occur
patient
respect
median
surviv
untreat
individu
report
year
larg
improv
sinc
introduct
ursodeoxychol
acid
udca
therapi
liver
transplant
patient
treat
udca
earli
stage
diseas
respond
well
therapi
may
reach
normal
life
expect
howev
benefici
mechan
udca
treatment
still
incomplet
understood
one
third
patient
fail
adequ
respond
udca
monotherapi
second
part
review
therefor
summar
rational
behind
udca
therapi
give
overview
futur
therapeut
option
current
studi
pbc
occur
individu
ethnic
origin
account
death
cirrhosi
primarili
affect
women
peak
incid
fifth
decad
life
uncommon
person
year
age
incid
preval
vari
strikingli
differ
geograph
region
qualiti
epidemiolog
studi
relat
pbc
rang
per
million
respect
highest
incid
preval
rate
report
uk
scandinavia
canada
usa
northern
hemispher
wherea
lowest
found
australia
clear
evid
support
exclud
concept
gradient
report
autoimmun
condit
increas
awar
condit
increas
avail
diagnost
tool
particular
serolog
test
led
frequent
earlier
diagnosi
pbc
half
patient
diagnos
today
pbc
asymptomat
present
gener
attract
attent
find
elev
serum
alkalin
phosphatas
ap
andor
total
serum
cholesterol
especi
asymptomat
patient
often
routin
checkup
diagnosi
pbc
made
confid
biochem
marker
cholestasi
particularli
alkalin
phosphatas
elev
persist
month
presenc
serum
ama
absenc
altern
explan
pbc
patient
ama
gener
present
high
titer
lowtit
ama
may
specif
may
disappear
retest
compat
histolog
find
confirm
diagnosi
allow
stage
therapeut
intervent
mani
case
histolog
workup
necessari
diagnos
pbc
biochem
test
serum
ap
commonli
elev
defin
togeth
ama
diagnosi
pbc
mildli
elev
serum
aminotransferas
alt
ast
usual
observ
pbc
diagnost
increas
serum
level
conjug
bilirubin
well
alter
prothrombin
time
serum
albumin
late
phenomena
pbc
like
cirrhot
state
unusu
diagnosi
howev
serum
bilirubin
strong
independ
predictor
surviv
high
impact
establish
model
prognosisserum
cholesterol
commonli
elev
patient
pbc
alik
cholestat
condit
increas
cholesterol
level
pbc
larg
caus
presenc
lpx
lpx
abnorm
lipid
particl
characterist
cholestat
liver
diseas
directli
deriv
biliari
lipid
regurgit
blood
upon
lipoprotein
fraction
lpx
usual
found
lowdens
lipoprotein
fraction
differ
lipoprotein
contrast
normal
lipoprotein
core
fill
neutral
lipid
lpx
consist
liposom
aqueou
lumen
phospholipid
free
cholesterol
lpx
taken
atherosclerot
plaqu
may
reduc
atherogen
lowdens
lipoprotein
ldl
cholesterol
prevent
ldl
oxid
accordingli
increas
serum
cholesterol
pbc
patient
associ
increas
risk
cardiovascular
diseas
contrast
longlast
pbc
associ
occurr
xanthomata
xanthelasma
hypercholesterolemia
pbc
patient
respons
statin
treatment
longterm
treatment
udca
also
reduc
serum
cholesterol
though
diagnost
thyroidstimul
hormon
level
assess
patient
believ
pbc
due
high
associ
pbc
thyroid
dysfunct
mainli
caus
hashimoto
thyroid
serolog
ama
autoantibodi
pathognomon
pbc
lead
diagnosi
high
specif
sensit
amaposit
individu
even
sign
cholestasi
andor
liver
inflamm
present
like
develop
pbc
mitchison
et
al
small
studi
evalu
liver
patholog
asymptomat
amaposit
level
individu
lack
ap
elev
inclus
two
abnorm
liver
histolog
find
diagnost
pbc
followup
subject
reveal
remain
amaposit
develop
biochem
evid
cholestasi
becam
symptomat
confirm
high
posit
predict
valu
posit
ama
test
develop
pbcsensit
ama
howev
although
high
limit
investig
report
patient
clinic
biochem
histolog
featur
pbc
despit
consist
neg
ama
test
immunofluoresc
specif
immunoblot
immunoenzymat
techniqu
overal
ama
seem
neg
patient
otherwis
featur
typic
pbc
ident
autoreact
cell
respons
critic
autoantigen
small
group
amaneg
patient
howev
may
erron
includ
patient
pbclike
symptom
induc
caus
autoimmun
patient
mutat
gene
patient
secret
reduc
amount
phospholipid
bile
harm
hepatocyt
cholangiocytesth
pattern
serum
immunoglobulin
fraction
pbc
character
elev
serum
igm
possibl
due
abnorm
chronic
b
cell
activ
tolllik
receptordepend
signal
howev
specif
find
limit
igm
level
commonli
use
diagnost
criteriumnonspecif
antinuclear
antibodi
ana
andor
smooth
muscl
antibodi
found
serum
one
third
patient
otherwis
clearcut
pbc
limit
diagnost
valu
contrast
specif
ana
direct
nuclear
bodi
envelop
protein
present
multipl
nuclear
dot
indirect
immunofluoresc
stain
present
perinuclear
rim
shown
specif
pbc
although
sensit
low
specif
ana
use
diagnost
marker
pbc
absenc
ama
titer
imag
ultrasound
examin
liver
biliari
tree
obligatori
cholestat
patient
order
differenti
intrahepat
extrahepat
cholestasi
biliari
system
appear
normal
serum
ama
present
radiolog
workup
necessari
abdomin
lymphadenopathi
particularli
hilar
region
liver
seen
patient
pbc
transient
elastographi
te
introduc
new
simpl
noninvas
imag
techniqu
determin
degre
fibrosi
patient
chronic
liver
diseas
mainli
chronic
hepat
c
corpechot
et
al
compar
liver
stiff
determin
te
fibroscanr
histolog
find
obtain
liver
biopsi
patient
pbc
n
primari
scleros
cholang
psc
n
show
highli
signific
correl
liver
stiff
degre
fibrosi
histolog
stage
studi
independ
cohort
pbc
patient
warrant
te
regard
establish
altern
liver
biopsi
stage
chronic
cholestat
liver
diseas
still
te
appear
attract
screen
tool
futur
therapeut
trial
may
help
overcom
limit
stage
accuraci
liver
biopsi
due
heterogen
distribut
inflamm
fibrosi
pbc
liver
biopsyhistolog
liver
biopsi
anymor
regard
mandatori
diagnosi
pbc
patient
elev
serum
marker
cholestasi
posit
serum
ama
may
help
exclud
potenti
caus
cholestat
diseas
assess
diseas
activ
stage
liver
biopsi
may
also
help
presenc
disproport
elev
serum
transaminas
andor
serum
igg
level
identifi
addit
altern
process
histolog
stage
pbc
stage
stage
determin
degre
peri
portal
inflamm
bile
duct
damag
prolifer
presenc
fibrosiscirrhosi
accord
ludwig
et
al
scheuer
stage
diseas
character
portal
inflamm
granulomat
destruct
bile
duct
although
granuloma
often
seen
stage
character
periport
hepat
bile
duct
prolifer
presenc
fibrou
septa
bridg
necrosi
defin
stage
cirrhosi
stage
find
fibrot
cirrhot
chang
stage
accompani
wors
prognosi
florid
duct
lesion
defin
focal
duct
obliter
granuloma
format
regard
typic
pbc
liver
uniformli
involv
featur
four
stage
pbc
found
one
biopsi
specimen
advanc
histolog
featur
use
histolog
stage
diagnosi
major
patient
asymptomat
present
eg
workup
elev
serum
level
ap
cholesterol
symptomat
patient
fatigu
pruritu
common
complaint
report
patient
present
respect
unexplain
discomfort
right
upper
quadrant
abdomen
report
approxim
patient
major
asymptomat
untreat
patient
overt
symptom
develop
within
year
although
one
third
may
remain
symptomfre
mani
year
fatigu
cours
diseas
pbc
patient
complain
chronic
fatigu
impair
qualiti
life
interf
daili
life
activ
correl
sever
liver
diseas
could
demonstr
associ
autonom
dysfunct
particular
orthostat
hypotens
sleep
disturb
excess
daytim
somnol
although
weak
depress
might
necessit
treatment
exact
pathophysiolog
mechan
lead
chronic
fatigu
pbc
cholestat
diseas
unravel
far
standard
therapi
pbc
udca
even
liver
transplant
may
fail
improv
often
disabl
symptom
pruritu
pbc
frequent
associ
pruritu
chronic
cholestat
liver
diseas
cours
diseas
pruritu
occur
patient
often
distress
symptom
develop
independ
degre
cholestasi
stage
diseas
pathogenesi
remain
poorli
understood
potenti
pruritogen
cholestasi
undefin
therapeut
efficaci
anion
exchang
resin
like
cholestyramin
pregnan
x
receptor
agonist
rifampicin
plasmapheresi
albumin
dialysi
well
nasobiliari
drainag
led
conclus
cholestasi
put
pruritogen
accumul
circul
secret
bile
undergo
enterohepat
cycl
itch
could
induc
local
skin
neuron
structur
bile
salt
metabolit
progesteron
metabolit
histamin
endogen
opioid
among
other
propos
caus
agent
howev
evid
key
role
suggest
pruritogen
cholestasi
weak
portal
hypertens
varic
hemorrhag
sign
portal
hypertens
secondari
fibrosi
cirrhosi
uncommon
first
present
occasion
describ
howev
portal
hypertens
determin
measur
portohepat
pressur
gradient
phg
common
pbc
stabl
treatment
improv
phg
predictor
surviv
metabol
bone
diseas
patient
pbc
report
increas
risk
osteoporosi
studi
report
literatur
remain
contradictori
patient
advanc
pbc
may
particular
risk
osteoporosi
may
present
osteoporosi
yet
otherwis
asymptomat
liver
diseas
develop
osteoporosi
pbc
patient
attribut
decreas
osteoblast
activ
increas
osteoclast
activ
metabol
vitamin
normal
pbc
malabsorpt
calcium
vitamin
may
occur
predominantli
latestag
diseas
pancreat
insuffici
celiac
diseas
associ
pbc
may
aggrav
malabsorpt
fatsolubl
vitamin
malabsorpt
secret
bile
bile
salt
insuffici
ie
bile
salt
drop
critic
micellar
level
duodenum
malabsorpt
fat
fatsolubl
vitamin
may
ensu
serum
level
vitamin
e
shown
low
minor
patient
primari
biliari
cirrhosi
prior
develop
jaundic
osteomalacia
bare
seen
pbc
liver
transplant
perform
patient
develop
complic
prolong
deep
jaundic
urinari
tract
infect
though
often
asymptomat
recurr
urinari
tract
infect
report
women
pbc
potenti
pathophysiolog
relev
escherichia
coli
strain
suggest
malign
report
rate
breast
carcinoma
women
pbc
differ
report
either
increas
risk
equal
risk
compar
healthi
populationhepatocellular
carcinoma
latestag
pbc
report
occur
rate
similar
kind
cirrhosi
seem
frequent
men
pbc
one
studi
report
averag
hcc
preval
advanc
pbc
women
men
associ
disord
number
mostli
immunemedi
diseas
commonli
observ
patient
pbc
thyroid
dysfunct
frequent
associ
pbc
often
predat
diagnosi
sicca
syndrom
seen
patient
incomplet
complet
crest
syndrom
calcinosi
cuti
raynaud
syndrom
esophag
motil
disord
sclerodactyli
teleangiectasia
uncommon
celiac
diseas
report
patient
far
commonli
associ
pbc
inflammatori
bowel
diseas
genet
factor
impact
pbc
pathogenesi
stronger
nearli
autoimmun
diseas
accordingli
concord
rate
seen
monozygot
twin
oppos
nearli
dizygot
twin
significantli
increas
incid
pbc
seen
rel
pbc
patient
rel
risk
firstdegre
rel
pbc
patient
higher
gener
popul
yield
preval
rate
interestingli
among
affect
monozygot
twin
though
age
diseas
onset
similar
progress
diseas
sever
vari
emphas
role
epigenet
probabl
environment
factor
difficult
identifi
distinct
suscept
gene
pbc
far
genet
associ
pbc
shown
major
histocompat
complex
encod
gene
pbc
appar
associ
famili
allel
although
mark
variat
observ
differ
ethnic
group
associ
haplotyp
seen
popul
european
origin
wherea
popul
asian
origin
associ
seen
allel
protect
associ
describ
signific
popul
differ
observ
associ
pbc
allel
well
protect
associ
recent
confirm
largest
seri
ever
report
includ
unrel
patient
itali
odd
ratio
develop
pbc
subject
wherea
reduc
subject
posit
carrier
studi
highlight
relev
geograph
variat
mark
differ
allel
associ
northern
southern
itali
associ
also
report
polymorph
gene
involv
innat
adapt
immun
allel
variat
tumor
necrosi
factor
cytotox
lymphocyt
antigen
key
regul
adapt
immun
system
repeatedli
associ
suscept
differ
autoimmun
diseas
type
diabet
mellitu
system
lupu
erythematosu
also
associ
pbc
although
associ
variant
suscept
pbc
could
demonstr
studi
poupon
et
al
recent
confirm
potenti
role
variant
pathogenesi
pbc
pbc
patient
two
independ
control
group
healthi
volunt
author
investig
distribut
newli
identifi
htsnp
select
candid
gene
two
relat
immun
encod
ten
gene
relat
bile
format
encod
hepatobiliari
transport
three
relat
adapt
respons
cholestasi
encod
nuclear
receptor
analysi
haplotypetag
singl
nucleotid
polymorph
htsnp
show
differ
distribut
pbc
control
confirm
potenti
role
pathogenesi
pbc
contrast
htsnp
ten
transport
gene
well
three
nuclear
receptor
gene
studi
equal
distribut
confirm
previou
studi
htsnp
key
transport
without
major
impact
strong
associ
allel
variant
rs
ct
diseas
progress
shown
interestingli
strong
associ
diseas
progress
also
shown
rs
ta
gene
encod
apic
anion
exchang
cholangiocyt
hepatocyt
case
presenc
variant
associ
delay
diseas
progress
multivari
cox
regress
variant
ta
independ
prognost
factor
diseas
progress
pbc
udca
treatment
addit
serum
bilirubin
alkalin
phosphatas
serum
albumin
level
establish
surrog
marker
prognosi
pbc
recent
landmark
genet
associ
studi
publish
associ
risk
diseas
unravel
loci
across
hla
class
ii
region
two
snp
interleukin
alpha
locu
one
snp
interleukin
receptor
beta
locu
one
previous
describ
snp
locu
associ
loci
describ
variou
associ
loci
describ
individu
popul
mostli
limit
size
howev
vast
major
confirm
independ
cohort
date
none
genet
associ
describ
pbc
proven
suffici
futur
genet
linkag
studi
affect
famili
well
associ
studi
larg
cohort
unrel
patient
may
disclos
genet
variant
confer
suscept
influenc
progress
sever
diseas
linkag
studi
await
pbc
remain
specul
whether
femal
preponder
gender
ratio
reflect
xchromosomelink
locu
suscept
altern
protect
role
ylink
gene
could
assum
genderspecif
exposur
environment
trigger
like
cosmet
nail
polish
discuss
howev
specul
pathomechanist
role
x
chromosom
gene
support
observ
increas
frequenc
x
chromosom
monosomi
pbc
well
autoimmun
diseas
increas
x
chromosom
monosomi
might
lead
haploinsuffici
specif
xlink
gene
therebi
increas
diseas
predisposit
case
report
pbc
patient
turner
syndrom
also
support
hypothesi
estrogen
signal
also
propos
play
role
homeostat
prolif
respons
cholangiocyt
pbc
accordingli
studi
polymorph
estrogen
receptor
gene
reveal
associ
diseas
least
popul
tissu
level
cholangiocyt
pbc
patient
earliest
diseas
stage
cholangiocyt
normal
control
express
estrogen
receptor
agent
abl
modul
estrogenreceptormedi
respons
tamoxifen
therefor
propos
novel
bec
homeostasi
target
therapi
case
report
support
hypothesi
yet
potenti
interest
therapeut
approach
undergon
formal
assess
clinic
trial
recent
alter
express
hepat
microrna
mirna
describ
liver
tissu
pbc
patient
certain
mirna
neg
regul
protein
code
gene
express
may
play
critic
role
variou
biolog
process
howev
causal
link
alter
mirna
express
develop
pbc
still
remain
unproven
despit
strong
evid
genet
background
pbc
epidemiolog
studi
earli
suggest
role
environment
factor
trigger
andor
exacerb
pbc
signific
role
environment
factor
support
identif
geograph
diseas
hot
spot
first
report
northeast
england
use
formal
cluster
analysi
origin
uk
analysi
report
increas
frequenc
pbc
former
industri
andor
coal
mine
area
anoth
recent
studi
new
york
examin
preval
pbc
psc
near
superfund
area
report
signific
cluster
pbc
surround
toxic
site
synopsi
observ
gave
rise
hypothesi
chemic
environment
factor
potenti
associ
contamin
land
could
either
trigger
diseas
caus
diseas
direct
toxic
effect
hypothesi
would
also
provid
one
possibl
explan
tissu
tropism
pbc
toxin
toxin
excret
bile
therebi
concentr
biliari
tree
observ
hormon
replac
therapi
frequent
use
nail
polish
link
risk
develop
pbc
support
potenti
impact
environment
factor
pathogenesi
pbc
smoke
also
seem
risk
factor
pbc
demonstr
acceler
progress
associ
exposur
chemic
environment
compound
xenobiot
includ
drug
pesticid
organ
molecul
variou
human
autoimmun
diseas
describ
summar
xenobiot
may
contribut
pathogenesi
pbc
trigger
autoimmun
reaction
differ
mechan
induct
autoimmun
xenobiot
propos
potenti
direct
toxic
effect
xenobiot
caus
cell
death
apoptosi
oncosi
induc
gener
immunogen
autoepitop
addit
chemic
modif
nativ
cellular
protein
remov
andor
exchang
hapten
shown
chang
process
antigenpres
cell
may
lead
present
cryptic
potenti
immunogen
peptid
furthermor
xenobiot
may
potenti
modifi
host
protein
form
neoantigen
neoantigenspecif
cell
b
cell
prime
may
crossreact
formerli
inert
nativ
autoantigen
accord
hypothesi
amano
et
al
studi
number
xenobiot
structur
similar
lipoic
acid
residu
epitop
pyruv
dehydrogenas
complex
main
autoreact
antigen
identifi
pbc
far
pbc
replac
lipoic
acid
certain
xenobiot
enhanc
reactiv
pbc
sera
epitop
particularli
one
xenobiot
acid
induc
reactiv
pbc
sera
stronger
nativ
lipoic
acid
residu
interestingli
methyl
ester
acid
violpeachlik
scent
use
ingredi
perfum
rank
chemic
compound
term
occup
exposur
femal
preponder
due
use
cosmet
among
environment
factor
suggest
potenti
caus
agent
pbc
particularli
differ
bacteria
discuss
earli
histolog
lesion
pbc
noncas
granuloma
observ
seen
granulomat
liver
diseas
includ
sarcoidosi
drug
reaction
interestingli
infect
furthermor
noncas
granuloma
uniqu
pbc
compar
autoimmun
patholog
led
suspicion
microbi
basi
pbc
support
hypothesi
certain
bacteria
found
contain
pdc
compon
fulli
crossreact
mammalian
form
propos
exposur
homologu
could
trigger
crossreact
immun
favor
bacteri
etiolog
recent
data
suggest
tolllik
receptor
ligand
induc
augment
inflammatori
respons
pbc
combin
presenc
crossreact
antigen
proinflammatori
environ
would
theoret
abl
break
toler
theoret
background
mind
earli
studi
associ
variou
bacteria
pbc
reattract
interest
e
coli
report
present
excess
fece
patient
pbc
addit
incid
urinari
tract
infect
often
induc
e
coli
high
pbc
patient
histori
urinari
tract
infect
increas
risk
pbc
anoth
microorgan
propos
candid
induct
pbc
novosphingobium
aromaticivoran
titer
antibodi
lipoyl
bacteri
protein
ubiquit
organ
metabol
organ
compound
includ
estrogen
higher
compar
e
coli
patient
pbc
antibodi
observ
larg
cohort
healthi
subject
lactobacilli
chlamydia
show
structur
homolog
autoantigen
although
reactiv
consider
less
either
e
coli
n
aromaticivoran
also
implic
put
pathogen
helicobact
pylori
mycobacterium
gordona
recent
case
pbc
follow
lactobacillu
vaccin
recurr
vagin
report
vaccin
contain
lactobacillu
salivariu
exert
high
homolog
betagalactosidas
lactobacillu
delbrueckii
lacd
crossreact
patient
autoantibodi
human
epitop
lacd
found
affin
lactobacillu
epitop
higher
nativ
mammalian
suggest
antimicrobi
reactiv
may
preced
selfmim
howev
ama
statu
patient
repetit
lactobacillu
vaccin
could
assess
causal
relat
lactobacillu
exposur
develop
pbc
remain
specul
also
studi
despit
intrigu
associ
compel
data
provid
show
one
individu
infecti
agent
reproduc
detect
patient
pbc
although
attract
model
bacteri
infect
caus
pbc
thu
support
littl
direct
evid
object
data
warrant
obtain
either
prospect
follow
cohort
epidemiolog
approach
confirm
role
bacteria
trigger
pbc
altern
infecti
agent
recent
propos
trigger
pbc
human
retroviru
identifi
liver
tissu
hilar
lymph
node
pbc
patient
em
analysi
liver
tissu
obtain
pbc
patient
reveal
retroviru
compat
particl
bec
periport
lymph
node
mous
mammari
tumor
viru
mmtv
detect
correl
aberr
distribut
perisinusoid
cell
homogen
periport
lymph
node
also
capac
infect
bec
cultur
induc
mark
phenotyp
chang
effect
could
abolish
irradi
cultur
media
suggest
infecti
agent
retrovir
infect
hypothet
could
caus
bec
damag
either
direct
viral
cytopath
effect
crossreact
viral
protein
selfpdc
molecular
mimicri
model
virusinduc
apoptosi
retrovir
infect
would
also
provid
explan
key
phenomena
pbc
pbc
recur
rapidli
transplant
clinic
manifest
includ
detect
ama
serum
aberr
express
amareact
protein
bec
histolog
evid
diseas
patient
respect
observ
associ
potent
immunosuppress
therapi
follow
transplant
earlier
aggress
recurr
pbc
also
interest
mmtv
replic
regul
part
progesteronerespons
glucocorticoid
regulatori
element
promot
region
offer
altern
explan
femal
preponder
seen
pbc
find
attract
attent
field
acknowledg
investig
point
need
clinic
trial
antiretrovir
therapi
subsequ
small
nonrandom
pilot
studi
therapi
combivir
lamivudin
zidovudin
improv
inflammatori
score
normal
ap
reduc
bile
duct
injuri
patient
pbc
find
await
confirm
random
control
trial
unfortun
major
find
outlin
vitro
studi
could
reproduc
independ
group
other
rais
concern
find
might
mainli
reflect
contamin
technic
artifact
independ
studi
larg
number
sera
pbc
patient
healthi
control
show
reactiv
mmtv
encod
protein
detect
immunohistochem
molecular
evid
mmtv
found
liver
specimen
peripher
blood
lymphocyt
also
specul
benefici
effect
antiretrovir
therapi
could
partli
explain
antiapoptot
properti
nucleosid
analog
furthermor
mechan
human
betaretroviru
would
enter
human
cholangiocyt
also
identifi
recent
studi
howev
strengthen
case
involv
retrovirus
immunemedi
liver
diseas
sera
patient
divers
chronic
liver
diseas
control
test
revers
transcriptas
activ
presenc
human
betaretroviru
polymeras
chain
reaction
revers
transcriptas
activ
detect
autoimmun
hepat
patient
pbc
subject
patient
viral
hepat
liver
patient
without
viral
autoimmun
pathogenesi
nonalcohol
fatti
liver
diseas
alcohol
liver
diseas
control
subject
polymeras
chain
reaction
pbc
sampl
posit
human
betaretroviru
compar
autoimmun
hepat
liver
diseas
nonliv
diseas
control
subject
data
confirm
retrovir
compound
pathogenesi
immunemedi
viral
liver
diseas
seem
attract
though
specif
pbc
thu
despit
intrigu
find
pathogenet
relev
retrovirus
develop
pbc
remain
enigmat
appendectomi
abdomin
surgeri
tonsillectomi
significantli
frequent
report
patient
pbc
epidemiolog
studi
north
america
howev
earlier
populationbas
case
control
studi
conduct
england
show
associ
recent
anoth
studi
provid
evid
least
associ
pbc
occurr
appendectomi
point
select
bia
present
previou
studi
done
north
america
linkag
appendectomi
theoret
attract
sinc
pbcspecif
immun
respons
highli
conserv
caseinolyt
proteas
p
yersinia
enterocolitica
patient
pbc
report
noteworthi
infect
enterocolitica
one
major
caus
acut
termin
ileiti
mimick
acut
append
autoimmun
phenomenon
dysregul
immun
respons
selfantigen
persist
result
inflammatori
tissu
damag
immun
respons
antigen
tightli
control
variou
pathway
whose
deregul
may
lead
autoimmun
respons
genet
predisposit
environment
factor
affect
suscept
deregul
toler
self
antigen
achiev
lymphopoiet
differenti
earli
life
highaffin
selfreact
lymphocyt
delet
primari
lymphoid
organ
thymu
bone
marrow
second
peripheri
activ
subset
lymphocyt
regulatori
cell
treg
dedic
regulatori
function
express
surfac
marker
transcript
factor
forkhead
box
addit
backup
along
matur
process
lymphocyt
describ
limit
induct
express
autoimmun
regulatori
mechan
includ
apoptosi
pathway
cytokin
receptor
chemokin
signal
cell
interact
intracellular
signal
transduct
accordingli
loss
selftoler
could
involv
multipl
fault
genet
origin
worth
mention
autoimmun
defin
presenc
autoantibodi
autoreact
lymphocyt
occur
natur
appear
natur
occur
autoantibodi
autoreact
lymphocyt
modul
suppress
earli
infect
clearanc
apoptot
bodi
immun
surveil
cancer
cell
among
other
review
yet
complet
unravel
system
regul
immun
respons
mechan
respons
develop
autoimmun
autoimmun
diseas
remain
enigmat
imbal
cell
regul
suffici
initi
propag
autoimmun
variou
chronic
inflammatori
diseas
inflammatori
bowel
diseas
ibd
rheumatoid
arthriti
line
concept
recent
transgen
anim
model
highlight
role
cell
regul
develop
autoimmun
diseas
instanc
mice
shown
develop
sever
anemia
ibd
possibl
due
decreas
number
treg
facilit
autoimmun
reactiv
presenc
prolifer
probabl
activ
tcell
absenc
receptor
anim
lead
prolifer
cell
decreas
number
treg
anoth
hypothesi
concept
molecular
mimicri
base
similar
pathogen
host
antigenderiv
epitop
recogn
immun
system
render
bacteria
virus
candid
induct
autoimmun
diseas
mechan
first
suggest
respons
develop
rheumat
fever
though
could
never
confirm
evid
suggest
associ
infecti
trigger
sever
system
autoimmun
diseas
includ
multipl
sclerosi
system
lupu
erythematosu
sle
rheumatoid
arthriti
autoantigen
unabl
elicit
primari
immun
respons
howev
cell
stimul
pathogen
crossreact
epitop
recogn
target
prerequisit
pathogenderiv
crossreact
epitop
suffici
differ
hostderiv
epitop
role
infecti
agent
develop
autoimmun
recent
review
elsewher
xenobiot
repres
anoth
environment
factor
foreign
human
organ
may
induc
immun
reaction
potenti
modifi
host
protein
render
immunogen
exampl
includ
drug
pesticid
organ
molecul
number
xenobiot
associ
sever
human
autoimmun
diseas
chemic
link
autoimmun
includ
mercuri
glomerulonephr
hydrazin
sle
iodin
autoimmun
thyrod
halothan
druginduc
hepat
halothaneinduc
liver
diseas
occur
suscept
individu
develop
immun
respons
trifluoroacetyl
tfa
selfprotein
upon
halothan
exposur
noteworthi
lipoyl
domain
human
pdc
also
recogn
antitfa
trigger
autoimmun
specul
increas
cell
turnov
specif
increas
cell
apoptosi
may
lead
exposur
otherwis
rare
expos
antigen
induct
immun
respons
self
enhanc
apoptosi
implic
sever
autoimmun
diseas
includ
hashimoto
thyreoid
hypothesi
would
also
provid
appeal
explan
tissu
specif
autoimmun
reaction
despit
often
ubiquit
express
target
autoantigen
howev
apoptosi
genuin
design
actual
prevent
inflammatori
reaction
cell
death
ingest
apoptot
cell
macrophag
induc
express
antiinflammatori
cytokin
promot
express
treg
suppress
autoimmun
respons
apoptosi
apoptosi
per
se
noninflammatori
process
lead
abnorm
antigen
present
especi
previous
sequest
antigen
evid
role
develop
autoimmun
diseas
howev
limit
particularli
organspecif
autoimmun
diseas
whether
apoptosisrel
mechan
lead
pbc
unclear
cholangiocyt
pbc
may
undergo
increas
cell
turnov
eg
due
metabol
stress
result
inadequ
immun
respons
strikingli
bec
patient
pbc
seem
significantli
increas
apoptot
stress
compar
healthi
control
patient
caus
inflammatori
reaction
liver
chronic
viral
hepat
psc
howev
yet
elucid
whether
effect
realli
caus
autoimmun
pbc
rather
consequ
increas
inflamm
pbc
associ
autoimmun
diseas
within
individu
among
famili
reflect
cluster
characterist
autoimmun
pbc
one
first
condit
presenc
autoantibodi
serum
identifi
antigen
specif
autoreact
respons
character
therefor
often
refer
model
autoimmun
diseas
predomin
autoreact
antibodi
pbc
ama
high
sensit
specif
virtual
diagnost
pbc
detect
serum
far
identifi
target
ama
member
famili
dehydrogenas
complex
includ
subunit
pyruv
dehydrogenas
complex
branch
chain
dehydrogenas
complex
acid
dehydrogenas
complex
dihydrolipoamid
dehydrogenas
bind
protein
local
within
inner
mitochondri
matrix
catalyz
oxid
decarboxyl
keto
acid
substrat
target
subunit
common
ntermin
domain
contain
singl
multipl
attach
site
lipoic
acid
cofactor
lysin
previou
studi
demonstr
domin
epitop
recogn
ama
locat
within
lipoyl
domain
target
antigen
autoreact
cell
infiltr
liver
pbc
recogn
domain
peptid
account
domin
autoreact
b
cell
cell
isol
liver
patient
pbc
found
exert
cytotox
puls
autolog
cell
peptid
support
hypothesi
cell
respons
contribut
bile
duct
injuri
pbc
remain
mysteri
epitop
local
inner
membran
mitochondria
becom
target
autoimmun
injuri
pbc
one
work
hypothesi
larg
enforc
gershwin
group
modif
xenobiot
may
alter
selfprotein
caus
breakdown
toler
facilit
autoimmun
respons
group
identifi
acid
residu
peptid
inner
domain
contain
lipoic
acid
cofactor
carri
lysin
elicit
strongest
reactiv
purifi
sera
pbc
patient
compar
number
potenti
epitop
subsequ
could
show
reaction
pbc
sera
significantli
increas
lipoyl
epitop
subsequ
identifi
residu
modifi
replac
lipoic
acid
seri
similar
distinct
synthet
structur
follow
modif
autoantibodi
patient
pbc
react
higher
affin
modifi
epitop
nativ
peptid
structur
induc
maxim
affin
demonstr
deriv
acid
compound
wide
use
cosmet
xenobiot
studi
group
also
shown
induc
pbclike
featur
differ
anim
model
immun
rabbit
coupl
bovin
serum
albumin
bsa
led
break
toler
judg
detect
ama
guinea
pig
immun
compound
led
develop
histolog
lesion
typic
autoimmun
cholang
concurr
appear
ama
albeit
long
latenc
month
recent
effort
result
develop
induc
anim
model
pbc
mice
anim
acid
coupl
bsa
short
followup
week
induc
manifest
autoimmun
cholang
typic
ama
increas
liver
lymphoid
cell
number
increas
liverinfiltr
cell
elev
level
serum
tumor
necrosi
factor
interferon
remark
unlik
mani
anim
model
pbc
report
immunogen
respons
liverspecif
inflamm
found
organ
liver
howev
model
still
disadvantag
eg
lack
develop
fibrosi
altern
complementari
concept
loss
selftoler
pbc
idea
underli
immun
deficit
concept
base
clinic
experiment
evid
pbc
exhibit
cluster
variou
autoimmun
disord
within
individu
famili
moreov
pbc
reduc
level
treg
suppress
immun
reaction
self
two
genet
manipul
mous
strain
spontan
occurr
pbclike
lymphoid
cholang
togeth
posit
within
sever
week
life
report
either
transgen
express
domin
neg
ii
receptor
rii
transgen
disrupt
receptor
alpha
highli
express
treg
perform
interestingli
b
cell
suppress
effect
inflammatori
respons
rii
model
pbc
role
signal
defect
develop
pbc
support
report
pbclike
liver
diseas
child
inborn
defici
receptor
alpha
addit
mous
model
describ
develop
autoimmun
biliari
diseas
found
test
amaposit
model
outlin
biliari
epithelium
infiltr
cell
wherea
granuloma
eosinophil
infiltr
seen
mice
convers
recent
shown
involv
variou
autoimmun
disord
pbc
liver
tissu
densiti
lymphocyt
infiltr
higher
healthi
liver
although
enhanc
densiti
cell
specif
pbc
line
observ
decreas
number
treg
may
illustr
counterplay
treg
cell
pbc
impress
progress
unravel
pathogenet
factor
pbc
past
decad
favor
genet
background
outstand
concord
rate
among
monozygot
twin
identifi
well
variou
genet
associ
cluster
distinct
hla
allel
among
other
allel
variat
anion
exchang
respect
describ
addit
compel
evid
environment
factor
requir
develop
pbc
xenobiot
capabl
modul
mammalian
protein
form
neoantigen
shown
induc
patholog
resembl
pbc
anim
model
furthermor
variou
infecti
agent
associ
pbc
human
although
direct
experiment
evid
role
pathogenesi
limit
lastli
disrupt
gene
involv
regul
immun
respons
ii
receptor
give
rise
histolog
serolog
chang
mimick
pbc
differ
anim
model
may
contribut
suscept
pbc
human
howev
common
caus
pathway
pbc
exist
could
yet
identifi
still
controversi
outlin
factor
predispos
pbc
may
well
specul
search
caus
pbc
might
lead
dark
identifi
pathogenet
factor
may
contribut
differ
extent
patient
caus
pbc
variabl
clinic
pictur
latter
highli
variabl
defin
pbc
today
presenc
cholestasi
ama
patient
amaposit
amaposit
hardli
develop
pbc
patient
respond
udca
treatment
one
third
diseas
progress
highli
variabl
mention
obviou
variabl
clinic
pictur
convent
call
pbc
may
well
emerg
individu
composit
describ
patholog
factor
jone
suggest
model
pbc
develop
distinguish
upstream
downstream
event
upstream
model
refer
caus
bec
loss
ductopenia
cholestasi
uniqu
pbc
probabl
uniqu
individu
patient
includ
genet
toxic
factor
infecti
agent
immunemedi
event
downstream
initi
mechan
nonspecif
patholog
event
occur
result
bile
duct
damag
hepatocyt
injuri
inflamm
fibrosi
independ
primari
individu
variabl
caus
downstream
event
hydrophob
bile
salt
retent
aggrav
underli
injuri
promot
hepat
cholangiocellular
damag
pathogenet
model
provid
explan
limit
efficaci
immunosuppress
drug
pbc
agent
prednisolon
treatment
pbc
limit
efficaci
may
mainli
affect
upstream
mechan
clinic
trial
agent
howev
larg
evalu
rel
advanc
symptomat
patient
individu
downstream
process
may
becom
predomin
balanc
evid
pbc
remain
strongli
favor
autoimmun
process
autoreact
attack
direct
epitop
within
follow
factor
principl
contribut
breakdown
selftoler
suggest
pbc
strong
compel
evid
support
molecular
mechan
crossreact
lipoic
acid
cofactor
environment
xenobiot
induc
autoimmunogen
modifi
anim
model
data
would
argu
crossreact
b
cell
respons
induc
xenobioticmodifi
selfpdc
process
epitop
spread
driven
antigenspecif
crossreact
b
cell
translat
breakdown
cell
toler
respons
effector
cell
mechan
thought
directli
respons
bec
loss
clinic
implic
observ
immunomodulatori
approach
therapi
play
role
particularli
earliest
stage
pbcaltern
addit
molecular
mimicri
mechan
crossreact
selfpdc
bacteri
potenti
viral
structur
may
support
induc
breakdown
tolerancemost
data
genet
associ
diseas
point
loci
gene
involv
immun
function
alter
regul
selftoler
possibl
support
induc
immun
reaction
express
normal
aberrantli
becsprimari
event
cholangiocellular
apoptosi
cell
damag
suggest
could
lead
aberr
present
selfantigen
creat
inflammatori
environ
potenti
trigger
immun
dysregul
suggest
mechan
includ
metabol
stress
possibl
trigger
dysfunct
transport
involv
cell
mainten
like
mechan
suggest
base
find
variant
strong
independ
prognost
factor
diseas
progress
pbc
udca
therapi
furthermor
secret
directli
toxic
environment
compound
bile
viral
infect
would
trigger
cholangiocellular
damagefin
function
morpholog
chang
bec
either
associ
process
outlin
factor
part
homeostat
mechan
design
retain
bec
function
may
lead
alter
selfrecognit
mechan
may
occur
simultan
sequenti
variabl
extent
result
breakdown
toler
immunemedi
liver
patholog
autoimmun
reaction
initi
variou
viciou
cycl
conceiv
inflammatori
reaction
secondari
loss
toler
lead
cholangiocellular
damag
apoptosi
increas
present
alter
selfpdc
increas
autoreact
bile
duct
loss
cholestasi
establish
retent
bile
salt
toxic
compound
perpetu
damag
bec
subsequ
entir
liver
mainten
viciou
cycl
may
support
immun
system
genet
dysregul
insuffici
capabl
suppress
autoimmun
reaction
outstand
paradox
pbc
pathogenesi
remain
tissu
tropism
immun
attack
small
intrahepat
bile
duct
although
mitochondri
target
ubiquit
express
protein
increas
vulner
primarili
affect
bec
therefor
prerequisit
pathogenesi
pbc
stain
bec
pbc
liver
monoclon
antibodi
mitochondri
autoantigen
show
specif
reaction
apic
surfac
found
control
nonpbcrel
mitochondri
protein
show
expect
cytoplasm
pattern
subsequ
demonstr
apic
stain
due
complex
auto
antimitochondri
iga
give
rise
specul
iga
might
player
immunemedi
destruct
bec
apoptosi
bec
propos
caus
aberr
neoantigen
present
respons
activ
attract
autoreact
lymphocyt
antibodi
unlik
cell
type
autoantibodi
recognit
abrog
apoptosi
probabl
glutathiol
moieti
antigen
persist
apoptot
bec
glutathiol
occur
cours
apoptot
marker
patient
pbc
peak
middl
stage
diseas
stage
rather
earlier
stage
could
sole
support
role
apoptosi
trigger
loss
selftoler
probabl
littl
number
cell
affect
rather
main
initi
event
pbc
put
posit
feedback
loop
apoptosi
autoreact
cell
respons
cholestat
bile
salt
retent
fail
replic
homeostasi
may
result
destruct
bec
bile
duct
structur
cholestasi
lead
retent
bile
salt
potenti
toxic
constitu
bile
system
particularli
hepatocyt
promot
hepatocellular
damag
chronic
state
induc
develop
fibrosi
cirrhosi
liver
recent
summar
paumgartn
pusl
gener
biochem
physiolog
principl
treat
cholestat
liver
diseas
broken
reduct
hepatocellular
uptak
bile
salt
organ
anion
stimul
metabol
hydrophob
bile
salt
toxic
compound
hydrophil
less
toxic
metabolit
stimul
orthograd
secret
bile
stimul
retrograd
secret
bile
salt
potenti
toxic
cholephil
system
circul
excret
kidney
protect
injur
cholangiocyt
toxic
effect
bile
salt
inhibit
apoptosi
caus
elev
level
bile
salt
inhibit
fibrosi
treatment
udca
address
postul
principl
recent
clinic
experiment
data
suggest
still
relev
effect
udca
bile
salt
uptak
bile
salt
metabol
demonstr
man
hepat
secret
patient
pbc
treat
udca
serum
level
bilirubin
endogen
bile
salt
decreas
effect
udca
seem
mediat
posttranscript
rather
transcript
mechan
mrna
level
key
transport
like
conjug
export
pump
bile
salt
export
pump
affect
udca
man
enhanc
hepat
protein
level
bsep
observ
udca
treatment
patient
gallston
may
contribut
improv
elimin
bile
salt
anim
model
cholestasi
udca
increas
densiti
bsep
canalicular
membran
rat
stimul
transport
target
insert
membran
cooper
protein
kinas
c
kinas
adepend
mechan
integrindepend
dual
signal
pathway
involv
mitogenactiv
protein
kinas
mapk
erk
shown
mediat
udcainduc
canalicular
bsep
insert
normal
cholestat
hepatocyt
whether
udcainduc
kinasemedi
phosphoryl
carrier
contribut
enhanc
canalicular
transport
densiti
activ
need
studi
detail
dilut
bile
flush
bile
duct
postul
import
function
cholangiocellular
bile
format
pbc
express
hepat
biliari
bicarbon
secret
impair
udca
stimul
express
bicarbon
secret
retrograd
secret
bile
salt
potenti
toxic
cholephil
adapt
mechan
cholestasi
basolater
conjug
transport
upregul
cholephil
bilirubin
glucuronid
adequ
secret
bile
leav
liver
cell
via
basolater
rout
contrast
postul
increas
retrograd
secret
udca
diminish
basolater
efflux
due
effect
stimul
orthograd
secret
potenti
toxic
compound
bile
protect
cholangiocyt
bile
high
concentr
hydrophob
bile
salt
exhibit
extracellular
cytotox
vitro
caus
cholangiocyt
injuri
physiolog
condit
pbc
inflammatori
bile
duct
injuri
may
aggrav
hydrophob
bile
salt
two
mechan
discuss
udca
protect
biliari
epithelium
toxic
effect
bile
ie
rel
reduct
hydrophob
bile
salt
enrich
phospholipid
bile
administ
recommend
dose
mgkgday
udca
content
may
rise
total
bile
salt
even
higher
percentag
dose
udca
increas
consequ
bile
composit
shift
toward
less
toxic
less
hydrophob
bile
saltsudca
administr
patient
gallston
increas
express
phospholipid
flippas
liver
might
explain
stimul
biliari
phospholipid
secret
udca
describ
patient
psc
secret
phospholipid
form
mix
micel
bile
salt
therebi
mitig
toxic
effect
cholangiocyt
inhibit
apoptosi
hydrophob
bile
salt
induc
hepatocellular
apoptosi
death
receptordepend
independ
mechan
effect
may
becom
relev
bile
salt
accumul
liver
cholestat
state
udca
exert
antiapoptot
effect
experiment
vivo
model
well
vitro
primari
human
hepatocyt
antiapoptot
effect
may
contribut
allevi
liver
injuri
udca
treatment
inhibit
fibrosi
releas
chemokin
cytokin
injur
cholangiocyt
infiltr
inflammatori
cell
well
hepat
stellat
cell
prolifer
induc
bile
salt
may
play
role
fibrogenesi
udca
report
delay
develop
sever
fibrosi
cirrhosi
pbc
may
relat
aforement
anticholestat
antiapoptot
effect
rather
direct
antifibrot
effect
udca
bile
salt
deriv
cdca
norudca
inhibit
fibrosi
bileductlig
mous
seem
mediat
antifibrot
effect
via
farnesoid
x
receptor
fxr
small
heterodim
partner
shp
mechan
action
norudca
remain
yet
unclear
immunomodulatori
properti
udca
controversi
discuss
past
glucocorticoid
receptor
rat
hepatocyt
activ
udca
ligandindepend
way
wherea
suppress
mhc
class
ii
express
found
glucocorticoidreceptordepend
remain
defin
whether
glucocorticoid
receptor
activ
uniqu
udca
thu
therapeut
relev
might
share
endogen
bile
saltscomprehens
review
molecular
action
udca
publish
recent
past
udca
current
consid
mainstay
therapi
pbc
random
doubleblind
placebocontrol
trial
consist
shown
udca
administ
today
standard
dose
mgkgday
improv
serum
biochem
marker
includ
bilirubin
import
prognost
marker
pbc
number
studi
demonstr
improv
histolog
featur
udca
combin
analysi
four
clinic
trial
includ
total
patient
independ
patient
udca
therapi
associ
delay
progress
mark
decreas
progress
rate
earlystag
diseas
late
histolog
stage
despit
effect
diseas
progress
sever
assess
effect
udca
treatment
longterm
surviv
difficult
combin
analysi
three
random
control
trial
includ
patient
total
treat
udca
year
reveal
improv
surviv
free
liver
transplant
patient
moder
sever
diseas
anoth
combin
analysi
five
studi
followup
least
year
quantifi
reduct
risk
death
liver
transplant
patient
treat
udca
longterm
followup
studi
cohort
patient
part
overlap
aforement
analys
report
surviv
without
liver
transplant
significantli
higher
udcatr
patient
compar
surviv
predict
mayo
model
recent
longterm
trial
franc
spain
netherland
shown
compar
result
surviv
rate
patient
earli
stage
diseas
biochem
respond
therapi
similar
control
popul
respons
defin
decreas
ap
pretreat
level
normal
year
barcelona
criteria
serum
bilirubin
mgdl
ap
n
ast
n
year
udca
treatment
pari
criteria
addit
nonrandom
control
studi
greec
confirm
patient
pbc
treat
udca
particularli
earli
stage
diseas
surviv
compar
gener
popul
despit
intrigu
find
benefici
effect
udca
surviv
repeatedli
question
larg
random
swedish
trial
fail
confirm
effect
udca
diseas
progress
surviv
dose
approxim
mgkgday
conclud
studi
dose
udca
lower
mgkgday
littl
benefit
followup
patient
us
canadian
trial
udca
signific
influenc
incid
endpoint
liver
transplant
death
also
metaanalysi
random
trial
could
confirm
signific
effect
udca
surviv
incid
liver
transplant
metaanalysi
howev
six
studi
year
followup
includ
two
studi
administ
udca
low
dose
mgkgday
less
metaanalys
suffer
similar
shortcom
may
therefor
miss
benefici
effect
udca
accordingli
metaanalys
includ
longterm
trial
followup
least
year
use
effect
dose
udca
mgkgday
verifi
treatment
udca
significantli
improv
qualiti
life
transplantfre
surviv
delay
histolog
progress
earlystag
patient
current
guidelin
therefor
recommend
treat
pbc
udca
use
dose
mgkgday
start
treatment
earli
two
third
patient
treat
accord
recommend
respond
adequ
defin
barcelona
pari
criteria
may
normal
life
expect
recent
studi
netherland
compris
patient
mean
followup
year
stress
import
earli
treatment
show
clear
surviv
benefit
patient
treat
earli
stage
diseas
normal
serum
bilirubin
albumin
level
start
therapi
remain
one
third
patient
fail
achiev
biochem
respons
accord
pari
barcelona
criteria
advanc
histolog
stage
start
medic
treatment
therapeut
option
limit
date
novel
approach
need
corticosteroid
immunosuppress
agent
evalu
therapeut
use
pbc
placebocontrol
trial
includ
patient
pbc
prednisolon
significantli
improv
serum
ap
level
igg
ama
diminish
deterior
liver
histolog
wherea
bone
loss
aggrav
combin
udca
prednisolon
comparison
udca
alon
result
signific
improv
histolog
featur
yet
unclear
whether
increas
express
isoform
contribut
benefici
effect
combin
treatment
udca
corticosteroid
pbc
experiment
enhanc
express
altern
isoform
enhanc
transport
capac
bicarbon
human
cholangiocyt
hepatocyt
cell
line
demonstr
express
biliari
bicarbon
secret
usual
diminish
pbc
seriou
side
effect
longterm
glucocorticoid
treatment
may
outweigh
potenti
benefit
respect
introduct
budesonid
nonhalogen
corticosteroid
extens
firstpass
metabol
promis
innov
control
doubleblind
trial
includ
patient
earlystag
pbc
compar
treatment
udca
plu
budesonid
udca
plu
placebo
combin
therapi
improv
biochem
histolog
featur
report
corticosteroidrel
side
effect
promis
result
howev
could
confirm
subsequ
studi
mayo
clinic
ad
budesonid
year
patient
suboptim
respons
udca
alon
margin
effect
serum
bilirubin
ap
level
contrast
mayo
risk
score
increas
signific
worsen
osteoporosi
open
trial
howev
includ
latestag
patient
may
part
explain
disappoint
result
found
shortterm
pharmacokinet
studi
administr
budesonid
cirrhot
pbc
patient
lead
high
plasma
level
budesonid
associ
seriou
advers
effect
therefor
avoid
finish
studi
includ
patient
stage
iii
n
random
trial
use
lower
dose
budesonid
effect
budesonid
plu
udca
compar
udca
alon
signific
improv
histolog
featur
observ
combin
group
top
benefici
biochem
effect
udca
alon
longterm
control
trial
requir
defin
whether
combin
udca
budesonid
provid
signific
benefit
patient
earlystag
pbc
inadequ
respond
udca
monotherapi
immunosuppress
agent
includ
azathioprin
cyclosporin
mycophenol
mofetil
methotrex
drug
antifibrot
properti
includ
penicillamin
colchicin
silymarin
shown
markedli
improv
natur
cours
diseas
associ
signific
toxic
longterm
treatment
novel
concept
medic
therapi
pbc
alon
combin
udca
recent
consid
particularli
use
patient
incomplet
respons
udca
among
other
antiretrovir
immunomodulatori
antioxid
approach
evalu
human
betaretroviru
controversi
debat
potenti
pathogen
pbc
outlin
antiretrovir
strategi
therefor
test
pbc
lamivudin
combin
zidovudin
combivir
normal
ap
reduc
bile
duct
injuri
pilot
trial
includ
patient
find
still
await
confirm
random
placebocontrol
studi
peroxisom
proliferatoractiv
receptor
agonist
bezafibr
report
improv
serum
liver
test
pbc
undergo
extens
evalu
patient
pbc
incomplet
respons
udca
futur
anticholestat
strategi
pbc
target
toward
stimul
transcript
key
hepatocellular
cholangiocellular
transport
order
improv
secretori
capac
cholestat
liver
first
result
pilot
studi
use
fxr
agonist
eagerli
await
udca
accept
treatment
cholestat
pruritu
icp
intrahepat
cholestasi
pregnanc
howev
effect
pruritu
variabl
pbc
present
convinc
data
antiprurit
effect
udca
pbc
avail
peripher
act
pruritogen
central
nervou
dysfunct
implic
pathogenesi
cholestat
pruritu
accord
two
concept
therapeut
intervent
current
studi
cholestat
pruritu
either
direct
toward
elimin
far
undefin
pruritogen
modul
central
neurotransmiss
pharmaceut
option
current
recommend
includ
anion
exchang
resin
cholestyramin
colestipol
bind
anion
amphipath
molecul
reduc
intestin
absorpt
system
accumul
despit
extens
clinic
experi
suggest
benefici
effect
patient
larg
clinic
trial
evalu
efficaci
exchang
resin
patient
lack
adequ
improv
treatment
rifampicin
may
help
rifampicin
semisynthet
antibiot
potent
pregnan
x
receptor
pxr
agonist
lead
induct
hepat
microsom
enzym
therebi
may
promot
metabol
potenti
pruritogen
thirdlin
option
opioid
antagonist
naloxon
nalmefen
naltrexon
found
reduc
itch
sever
patient
pbc
select
serotonin
reuptak
inhibitor
sertralin
report
improv
cholestat
pruritu
small
clinic
trial
recent
consid
fourthlin
treatment
option
experiment
approach
includ
receptor
type
antagonist
cannabinoid
subhypnot
dose
propofol
plasmapheresi
albumin
dialysi
nasobiliari
drainag
desper
case
although
adequ
trial
lack
liver
transplant
consid
seriou
case
strategi
fail
even
liver
function
still
conserv
specif
medic
therapi
fatigu
associ
chronic
cholestasi
yet
defin
udca
treatment
seem
limit
benefici
effect
fatigu
pbc
oral
supplement
antioxid
show
promis
result
pilot
studi
benefici
effect
random
placebocontrol
crossov
trial
independ
underli
diseas
alter
serotoninerg
neurotransmiss
implic
develop
fatigu
serotonin
receptor
antagonist
ondansetron
howev
significantli
reduc
fatigu
compar
placebo
random
placebocontrol
trial
select
serotonin
reuptak
inhibitor
fluvoxamin
fluoxetin
also
fail
exert
benefici
effect
fatigu
patient
group
seri
pbc
patient
excess
daytim
sleepi
central
act
agent
modafinil
investig
openlabel
studi
signific
improv
seen
epworth
sleepi
scale
score
fatigu
sever
assess
fatigu
domain
score
drug
stop
due
side
effect
consider
part
patient
end
studi
contrast
pruritu
fatigu
may
improv
significantli
follow
liver
transplant
independ
etiolog
bone
miner
loss
recogn
complic
cholestat
liver
diseas
pbc
moder
increas
absolut
rel
fractur
risk
compar
gener
popul
treatment
underli
liver
diseas
udca
prevent
bone
loss
pbc
calcium
vitamin
supplement
usual
recommend
osteoporosi
although
role
prevent
osteoporosi
fractur
chronic
liver
diseas
unclear
altern
intervent
prevent
treat
osteoporosi
liver
diseas
test
studi
parenter
calcitonin
test
one
control
trial
month
ineffect
halt
bone
loss
patient
pbc
wherea
hormon
replac
therapi
demonstr
improv
vertebr
bone
densiti
pbc
larg
clinic
trial
howev
hormon
replac
therapi
associ
seriou
side
effect
includ
risk
breast
cancer
coronari
arteri
diseas
thromboembol
limit
use
prevent
fractur
osteoporosi
use
bisphosphon
controversi
placebocontrol
trial
cyclic
etidron
significantli
improv
bone
densiti
also
treatment
clodron
plu
calciumvitamin
improv
osteopenia
women
pbc
prospect
studi
two
control
trial
howev
alendron
significantli
improv
spine
femor
bone
miner
densiti
compar
placebo
greater
antiresorpt
activ
etidron
accord
current
guidelin
supplement
calcium
mgday
vitamin
iuday
though
evidencebas
consid
patient
cholestat
liver
diseas
alendron
bisphosphon
recommend
score
dexa
follow
patholog
fractur
liver
transplant
treatment
choic
patient
latestag
pbc
indic
decompens
cirrhosi
treatmentresist
ascit
recurr
spontan
bacteri
periton
encephalopathi
recurr
varic
bleed
hepatocellular
carcinoma
highli
select
patient
see
treatmentresist
pruritu
absenc
decompens
cirrhosi
may
indic
transplant
sever
osteoporosi
surviv
rate
year
report
diseas
recur
year
transplant
usual
display
mild
cours
immunosuppress
treatment
